NCT03530527

Brief Summary

Biliary drainage is the mainstay of the palliative treatment in patients with inoperable malignant bile duct stricture. Endoscopic retrograde cholangiopancreatography (ERCP) is the cornerstone of biliary drainage method in these patients. However, ERCP is sometime unsuccessful to perform because of the presence of the high grade biliary stricture, tumor invasion of duodenum and ampulla of vater and surgically altered gastrointestinal anatomy. Endoscopic ultrasound (EUS) guided biliary drainage has been emerged as an alternative procedure to traditional surgical bypass and percutaneous trans hepatic biliary drainage after failed ERCP. There were few data to directly compare between ERCP and EUS guided biliary drainage and in patients with malignant high grade biliary stricture.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 8, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

May 21, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

August 20, 2018

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 28, 2018

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2019

Completed
Last Updated

April 1, 2021

Status Verified

March 1, 2021

Enrollment Period

3 months

First QC Date

May 8, 2018

Last Update Submit

March 26, 2021

Conditions

Keywords

ERCPEndoscopic ultrasound (EUS) guided biliary drainage

Outcome Measures

Primary Outcomes (1)

  • Technical success rate

    The number of patients with success of placement of stent in the desired. location

    24 hours

Secondary Outcomes (5)

  • Clinical success rates

    2 weeks

  • Total procedure time

    24 hours

  • The complication rates

    4 weeks

  • The mortality rates

    1 weeks

  • Stent patency

    12 weeks

Study Arms (2)

ERCP with biliary stenting

ACTIVE COMPARATOR

Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.

Procedure: ERCP with biliary stenting

EUS guided biliary drainage

ACTIVE COMPARATOR

Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.

Procedure: EUS guided biliary drainage

Interventions

ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.

Also known as: G1
ERCP with biliary stenting

EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.

Also known as: G2
EUS guided biliary drainage

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • distant metastasis
  • major vascular involvement (unreconstructible Superior mesenteric vein/Portal vein, superior mesenteric artery, common hepatic artery and celiac artery)
  • metastasis to lymphnode beyond the field or surgery IV) Jaundice, total bilirubin ≥15 mg/dl and/ or Common bile duct diameter ≥12 mm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

NKC Institue of Gastroenterology and Hepatology, Prince of Songkla University

Hat Yai, Changwat Songkhla, 90110, Thailand

Location

Prince of Songkla University

Hat Yai, Changwat Songkhla, 90230, Thailand

Location

MeSH Terms

Interventions

Cholangiopancreatography, Endoscopic Retrograde

Intervention Hierarchy (Ancestors)

CholangiographyRadiography, AbdominalRadiographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, Digestive SystemEndoscopy, Digestive SystemEndoscopyDiagnostic Techniques, SurgicalDigestive System Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical Procedures

Study Officials

  • Nisa Netinatsunton, MD.

    NKC Institute of Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand, 90110.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Secretory of NKC Institute of Gastroenterology and Hepatology

Study Record Dates

First Submitted

May 8, 2018

First Posted

May 21, 2018

Study Start

August 20, 2018

Primary Completion

November 28, 2018

Study Completion

December 15, 2019

Last Updated

April 1, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

The individual data of patients participating in the study are not available for public sharing since the investigators did not obtain the consent to share the data of patient.

Locations